Background
There are conflicting data regarding baseline determinants of virological non-suppression outcomes in persons with HIV who initiate antiretroviral treatment (ART). We evaluated the impact of different baseline variables in the RESPOND cohort.
Methods
We included treatment-naïve participants aged ≥18 who initiated 3-drug ART, in 2014-2020. We assessed the odds of virological suppression (VS) at weeks 48 and 96 using logistic regression. Viral blips, low-level viremia (LLV), residual viremia (RV) and virological failure (VF) rates were assessed using Cox regression.
Results
Out of 4,310 eligible participants, 72% initiated integrase strand transfer inhibitor (INSTI)-based regimens. At 48 and 96 weeks, 91·0% and 93·3% achieved VS, respectively. At 48 weeks, Kaplan-Meier estimates of rates of viral blips were 9·6%, LLV 2·1%, RV 22·2% and VF 2·1%. Baseline HIV-1 RNA >100,000 copies/mL and CD4+ count ≤200 cells/µL were negatively associated with VS at weeks 48 (aOR 0·51; 95%CI:0·39-0·68 and 0·40; 95%CI:0·27-0·58, respectively) and 96, and with significantly higher rates of blips, LLV and RV. CD4+ counts ≤200 cells/µL were associated with higher risk of VF (aHR 3·12; 95%CI:2·02-4·83). Results were consistent in those starting INSTIs versus other regimens and those initiating dolutegravir versus other INSTIs.
Conclusions
Initial high HIV-1 RNA and low CD4+ counts are associated with lower rates of VS at 48 and 96 weeks and higher rates of viral blips, LLV and RV. Low baseline CD4+ counts are associated with higher VF rates.These associations remain with INSTI- and specifically dolutegravir-based regimens. These findings suggest that the impact of these baseline determinants is independent of the ART regimen initiated.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.